Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Feb 25, 2019 5:14pm
89 Views
Post# 29411295

RE:RE:RE:Katama Factsheet cached

RE:RE:RE:Katama Factsheet cachedOn the right side of the doc they also talk about what proceeds would be used for so resumably that doc was used for finance raising. Dont know if they succeeded or failed. If this is essentially the same team thats at Angiochem it could represent them focussing on that as it approaches some important milestones. But you're right, can't ignore the basic valuation here, but you can't always relate a commercial deadend for an organization with a clinical deadend for the projects. It does seem like theratech is inheriting their setup at UQAM which I'm assuming is connected in some way to Beliveau's research group there. In the cc this morning beliveau was gushing about the work they plan to publish this year on the biodistribution of the drug.

palinc2000 wrote: It appears from the fact sheet that they have been looking to partner with oharmas with propietary molecules...That did not work out...
So they are basically selling all their research for 2 million dollrs now plus maybe another 900k if subsidies are received,,,,,,and maybe nothing else if they dont achieve the milestones in 2 -3 years from now
Moreover all they are getting from TH is cash ,,,,,nothing else 
I dont think you need to be a scientist to think that maybe their belief in success is not great .




PoorOpinion wrote: How would you read todays deal from Katana's perspective?
Beliveau is connected with Angiochem which focuses on peptides that cross the blood brain barrier and has oncology drugs in phase III.




Bullboard Posts